BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions
about
Precision medicine for cancer with next-generation functional diagnosticsCancer stem cells--important players in tumor therapy resistanceTumor immunotherapy: lessons from autoimmunityThe BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their AlkalinizationCaspase-8 activation by TRAIL monotherapy predicts responses to IAPi and TRAIL combination treatment in breast cancer cell linesMorroniside protects SK-N-SH human neuroblastoma cells against H2O2-induced damage.Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infectionEfficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia.Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.Potent and specific peptide inhibitors of human pro-survival protein Bcl-xL.SORTCERY-A High-Throughput Method to Affinity Rank Peptide Ligands.Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).Host-based Prophylaxis Successfully Targets Liver Stage Malaria Parasites.BH3 Profiling Reveals Selectivity by Herpesviruses for Specific Bcl-2 Proteins To Mediate Survival of Latently Infected Cells.Selective peptide inhibitors of antiapoptotic cellular and viral Bcl-2 proteins lead to cytochrome c release during latent Kaposi's sarcoma-associated herpesvirus infection.Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.Hematologic malignancies: newer strategies to counter the BCL-2 protein.hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents.Monte carlo study elucidates the type 1/type 2 choice in apoptotic death signaling in healthy and cancer cells.KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches.Biphasic ROS production, p53 and BIK dictate the mode of cell death in response to DNA damage in colon cancer cellsMolecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib.The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.Designing helical peptide inhibitors of protein-protein interactionsSurvival control of malignant lymphocytes by anti-apoptotic MCL-1.An outline of main factors of drug resistance influencing cancer therapy.Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinicPhosphorylation of the proapoptotic BH3-only protein bid primes mitochondria for apoptosis during mitotic arrest.Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice.Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine.Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling.A transgenic mouse model to inducibly target prosurvival Bcl2 proteins with selective BH3 peptides in vivo.Low probability activation of Bax/Bak can induce selective killing of cancer cells by generating heterogeneity in apoptosis.Combined venetoclax and alvocidib in acute myeloid leukemia.
P2860
Q26780232-61B3792F-8FCE-471F-9C31-B349075983A1Q26823015-D716AD47-F6FD-4D41-961E-DC2012D192A1Q26866179-0AAB707D-BD9A-42C4-8C67-88415F7552F0Q27318794-96A48724-2126-4815-8CC7-FAE410DC0F11Q30398758-4A6B24B3-A8FE-473D-997B-49CDED02359EQ32179652-C7206C39-38A4-4B69-95B8-0765B3F8AC1BQ33658144-046BC7A8-4C1B-4B40-A0E6-79FDF5BD3F54Q33702409-738D85F6-893F-4304-93FC-302ADEB05C54Q34231324-28C718CC-9E25-4590-842F-C70B4D838E50Q34515007-895747F0-4560-471D-9A7D-922AA7F00939Q35170975-1488B62E-8B40-41F3-B1B9-87E38B8FBDDBQ35328717-2C122562-A3D6-423A-ACD3-91D1EB0FB1EAQ35543223-BF1C89B4-412D-472C-B866-373F19960714Q35594843-B60567C9-26E9-48E4-8F5B-2720BA6F8517Q35641404-C3A0DD39-51B7-4E62-87BA-DF99C47BB5A6Q35802945-8BDBF597-22BB-454F-B4A5-0720DD30E53CQ35938054-BD4276C1-7AA1-4C87-A8EE-18915A159962Q35979110-50BC2F1B-7CF0-4323-A0FB-DDDA01B6C61DQ37657934-A71CEE59-7F5A-4034-AB92-3C385C6937DBQ37679250-22BB0814-5191-4809-BA34-78BDCBB702FAQ37693609-AB153A8B-AC74-4C40-A14B-DB00233634BEQ38148218-67F8E878-6498-4C9F-84D6-F9906DAD363FQ38630410-A08FA691-F083-40F8-9ADA-1A487077A9D3Q38636162-7D7E7424-A0AB-4E27-ABF1-99D26E6057F4Q38725415-D21AE88E-8673-4D22-810C-C996F3BD8589Q38766548-53FD73B8-2E5F-4EC8-BE9C-1E144D9DD986Q38819761-72043D44-F783-478B-AB83-AE3C1AF966A2Q38914858-2FC4211A-DADC-456E-ABB4-9D5799441344Q38933079-9256CEC3-79DB-4B78-8F6C-B325DEF8451FQ38935027-5E471D5B-CC25-4F22-8254-186D013F2FC5Q39001169-02AC8968-A135-4332-BA0C-A2914F13D080Q39093595-CCCC74B3-4E30-417D-B4DC-BA1E44FD7EAFQ39175665-212CA9B3-E1F9-428F-B3F0-7549DFD624C3Q39267135-5DEB2D36-D27C-4274-A171-1BAA1F742291Q41360967-58ECBAB1-0A01-4F01-A0B7-73752224295CQ42117299-29B02E90-7A0C-414F-8F29-FB74238A73EFQ42328311-77485092-8192-4A7E-A165-65389A3907BBQ43217834-0423F6A4-A511-49F1-9667-F9530411004EQ44357715-04C88EDB-4376-460D-BB5C-933E715F0DB8Q47105216-612386B7-ED4D-471A-AB69-30E70B396D61
P2860
BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
BH3 profiling--measuring integ ...... to predict cell fate decisions
@ast
BH3 profiling--measuring integ ...... to predict cell fate decisions
@en
BH3 profiling--measuring integ ...... to predict cell fate decisions
@nl
type
label
BH3 profiling--measuring integ ...... to predict cell fate decisions
@ast
BH3 profiling--measuring integ ...... to predict cell fate decisions
@en
BH3 profiling--measuring integ ...... to predict cell fate decisions
@nl
prefLabel
BH3 profiling--measuring integ ...... to predict cell fate decisions
@ast
BH3 profiling--measuring integ ...... to predict cell fate decisions
@en
BH3 profiling--measuring integ ...... to predict cell fate decisions
@nl
P2860
P1433
P1476
BH3 profiling--measuring integ ...... to predict cell fate decisions
@en
P2093
Anthony Letai
P2860
P304
P356
10.1016/J.CANLET.2011.12.021
P407
P577
2012-01-08T00:00:00Z